Chardan Capital Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $210.00

Palvella Therapeutics (NASDAQ:PVLA) had its price objective increased by research analysts at Chardan Capital from $174.00 to $210.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s price target would indicate a potential upside of 75.66% from the stock’s current price.

PVLA has been the topic of a number of other reports. Raymond James Financial reiterated a “strong-buy” rating and set a $193.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. UBS Group restated a “buy” rating and set a $143.00 target price on shares of Palvella Therapeutics in a research report on Monday, December 15th. Oppenheimer reiterated an “outperform” rating and issued a $200.00 price target on shares of Palvella Therapeutics in a research report on Monday, December 15th. Finally, Truist Financial lifted their price objective on Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $170.94.

Palvella Therapeutics Price Performance

Shares of NASDAQ:PVLA traded up $31.71 during mid-day trading on Tuesday, reaching $119.55. 935,374 shares of the company were exchanged, compared to its average volume of 280,648. Palvella Therapeutics has a 1 year low of $18.23 and a 1 year high of $127.69. The firm’s 50-day simple moving average is $91.58 and its 200 day simple moving average is $77.95. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -45.46 and a beta of -0.16.

Insider Activity

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. First Light Asset Management LLC acquired a new position in Palvella Therapeutics in the 3rd quarter valued at approximately $33,949,000. Summit Partners Public Asset Management LLC lifted its stake in shares of Palvella Therapeutics by 1,016.0% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock valued at $40,761,000 after purchasing an additional 354,525 shares during the period. Federated Hermes Inc. acquired a new stake in shares of Palvella Therapeutics during the third quarter worth $21,255,000. Vanguard Group Inc. increased its holdings in Palvella Therapeutics by 202.0% in the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after purchasing an additional 330,847 shares during the last quarter. Finally, State Street Corp boosted its holdings in Palvella Therapeutics by 206.3% during the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after buying an additional 283,211 shares during the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.